In Brief
Natural product indole-3-carbinol (I3C), commonly found in cruciferous vegetables, has antiproliferative effects in cancer cells. Rothman et al. show that for one class of the synthetic derivatives of I3C, N-BICs, the first step in their mechanism of anticancer action is conversion to reactive electrophiles mediated by SULT1A1.
INTRODUCTION
The N-benzyl indole carbinols (N-BICs) are synthetic analogs of the natural product indole-3-carbinol (I3C) ( Figure 1A ), commonly found in cruciferous vegetables and reported to have antiproliferative properties in cancer cells (Aggarwal and Ichikawa, 2005; Bradlow et al., 1999; Chinni et al., 2001; Safe et al., 2008; Wang et al., 2013; Weng et al., 2008) . I3C is an inactive acid-sensitive molecule proposed to be activated upon contact with gastric acids after consumption of Brassica vegetables. The stomach acid renders the molecule self-reactive, forming di-indoyl-methane (DIM) as well as other products (Grose and Bjeldanes, 1992) . Notably, DIM is widely commercially available as a natural therapy for the treatment of breast, uterine, and colon cancer, among other indications (Biersack and Schobert, 2012; Chen et al., 2013; Li et al., 2013; Sarkar and Li, 2009; Vivar et al., 2010) . It is speculated to act in the estrogen pathway, although this claim is controversial. The N-BICs ( Figure 1A ) differ from the parent I3C by virtue of having a benzyl group off of the indole nitrogen, rendering them more stable than the parent to acid (Aronchik et al., 2012; Nguyen et al., 2010) .
To date the N-BICs mechanism of action has remained unclear. Nguyen et al. (2010) identified an N-benzyl derivative of I3C, which is a more potent analog of I3C in killing estrogenresponsive (MCF-7) and estrogen-independent (MDA-MB-231) human breast cancer cells. They further suggested that the parent and analogs are elastase inhibitors that disrupt cyclin E protein processing. Other studies have suggested that oncrasin, an aldehyde analog of N-BICs, selectively kills mutant K-Ras cell lines (Guo et al., 2008) ; its antitumor activity is reported to be through activating JNK and inhibiting STAT3 (Guo et al., 2011; Gupta et al., 2013) .
Sulfotransferase 1A1 (SULT1A1) and other SULTs are phase II metabolic enzymes, which append a sulfate group to an aromatic or aliphatic hydroxyl group on xenobiotic compounds. This renders the compound more soluble for the purpose of excretion, and often less toxic or non-toxic. However, the sulfonated compound may also be rendered an electrophile, as the sulfate is a good leaving group. Many common drugs are substrates for SULTs; for example, acetaminophen, minoxidil, and dopamine are all SULT substrates (James and Ambadapadi, 2013; Wang and James, 2006) .
Here, we demonstrate that N-BICs selectively kill cancer cells, expressing high levels of SULT1A1. Furthermore, we understand that SULT1A1 activates the N-BICs by rendering the compounds strong electrophiles which can alkylate multiple proteins in the cell, and induce cell death and tumor suppression.
RESULTS

Identification of N-BICs
Identification of a drug that differentially targets tumors harboring p53 genetic alterations would be of tremendous value to the medical community. To identify such a molecule we embarked on a chemical genetics approach using p53 isogenic cell lines. Engineered HCT116 cells harboring different p53 status (wild-type [WT] , mutant [R248W], or null) (Sur et al., 2009) were treated with the Novartis Compound Library using ultrahigh-throughput screening technologies to identify those that could selectively kill the mutant or null strains. Cell viability was used as the primary screening assay, and promising hit molecules were subsequently tested in a colony formation assay. From these efforts a promising candidate series emerged, as exemplified by N-BIC 1 ( Figure 1A) .
The cytotoxic profile for the compound is shown in Figure 1B . In a reconfirmation dose-response format of the primary cell viability assay across the three cell lines, N-BIC 1 most potently and effectively kills HCT116-p53 mutant cells with an IC 50 of 300 nM and a maximum effect of 60% (D and E) Differential selectivity of (D) N-BIC 2 and (E) doxorubicin in CCLE profiling. Each point represents one cell line; x axis denotes the concentration of compound at which the curve crosses 50% cell death (cross point); and y axis denotes the maximum cell death when normalized to DMSO (0%) and the broadly cytotoxic MG132 (100%).
inhibition of viability (100% viability is DMSO treatment, 0% viability is no cells). The compound is slightly less potent and significantly less efficacious on p53-WT cells and has no effect on p53 null cells, suggesting a phenotype associated specifically with the p53 mutant genotype. This trend was replicated in colony formation assays (Figure 1C) . We wanted to discover whether this observation in isogenic lines would hold in a larger set of non-engineered cancer cell lines. To better understand what drives the differential sensitivity, N-BIC 1 and several analogs were subjected to a larger viability panel assessment.
Characterization of Cell Sensitivity to N-BICs
Several N-BICs were passed through a patient stratification platform termed the cell line profiling platform (CLiP). This approach sequentially tests compounds for viability effects in an eightpoint dose-response format across approximately 500 cell lines derived from the Cancer Cell Line Encyclopedia (CCLE). The CCLE comprises a compilation of well-characterized genetic and expression-based features from human cancer cell lines. When coupled with pharmacological profiles across the 500 cell lines used in CLiP, this collection allows identification of genetic-, lineage-, and gene-expression-based predictors of drug sensitivity (Barretina et al., 2012) .
The compound N-BIC 2 ( Figure 1A ) was tested in this subset of the CCLE and produced a selective profile ( Figure 1D ). Each dose-response curve for a given cell line is represented as a single spot on the graph where the x axis is a measure of potency (crossing point) and the y axis is a measure of efficacy (maximal inhibition compared with a broadly cytotoxic control). Cell lines on the lower left of the plot are considered highly sensitive to compound and cell lines on the upper right are considered insensitive. Each N-BIC had a relatively specific profile and was able to kill a subset of cells (deemed N-BICs sensitive) without affecting most of the cell lines in the experiment (deemed N-BICs insensitive). This is in contrast to standard-of-care compounds, such as doxorubicin, which demonstrate general toxicity across the cell lines ( Figure 1E ). Given the richness of information available on the CCLE lines, this differential cytotoxicity can be a powerful tool to determine target(s) and/or potential mechanism(s) of action for a compound of unknown function.
SULT1A1 Identified as a Sensitivity Feature
An in-depth analytical comparison between sensitive and insensitive cells was used to identify the characteristic features associated with sensitivity. Sensitive cells were defined as those with a crossing point of less than 2 mM, and insensitive cells were defined as those with a crossing point greater than 6.5 mM. The analysis identifies mutations, amplifications, mRNA levels, or lineages as features that differ between the sensitive and insensitive cell line populations. The data revealed that p53 mutational status was not a statistically distinguishing feature; however, SULT1A1 expression was noted as a strikingly statistically significant feature (p value for N-BIC 1, 2.38 3 10 À19 ; p value for N-BIC 2, 2.99 3 10 À23 ) which could distinguish the two populations. Sensitivity was highly correlated with SULT1A1 mRNA levels; that is, cells with high SULT1A1 mRNA were effectively killed by N-BICs and cells with low SULT1A1 mRNA were resistant to N-BICs ( Figure 2A ). Furthermore, there is good correlation of SULT1A1 expression and sensitivity across different lineages, especially in breast, kidney, ovary, and liver cancer cells ( Figure 2B ). Liver cells provided a good lineage-matched set of lines to further validate the correlation between compound sensitivity and SULT1A1 expression; there are 16 liver-derived cancer cell lines included in the CLiP set with a wide array of SULT1A1 expression. Figure 2C shows the clear correlation of SULT1A level with sensitivity in these cells. To further validate the profiling data, we selected two cell lines each with low, medium, or high SULT1A1 based on mRNA profiling data, to assess mRNA and protein levels ( Figure 2D ). There is a good correlation between protein levels and observed CLiP sensitivity for the cancer cell lines. To confirm sensitivity among all of these liver lines, cell viability upon compound treatment was measured. N-BIC 1 showed strong selectivity, potently inhibiting the growth of cells with high SULT1A1 level. In contrast, cisplatin repressed all the cell growth with similar potency ( Figure 2E ).
SULT1A1 Is Required for Cellular Sensitivity
To confirm the necessity of SULT1A1 for cell sensitivity to N-BICs, Caov-3 cells were subjected to SULT1A1 knockdown followed by compound treatment. Several short-hairpin RNAs (shRNAs) were assessed for knockdown efficiency of SULT1A1; each shRNA produced a different knockdown efficiency, as observed in Caov-3 cells ( Figure 3A) . shRNA3 showed the most effective knockdown and rendered the cell line insensitive to compound treatment. Of note, the relative potency of the shRNAs for knockdown was directly correlated to modulating sensitivity to compound: shRNA3 was most effective and rendered the cells insensitive, shRNA2 was non-functional and had minimal effect, and shRNA1 had an intermediate knockdown with a partial rescue of sensitivity. Similar results were observed in the engineered HCT116 p53 mutant cells, thus strengthening the correlation of SULT1A1 level with sensitivity to N-BICs (data not shown).
To determine the sufficiency of SULT1A1 for compound sensitivity, we performed a reciprocal experiment, introducing the gene into a cell line with undetectable SULT1A1 to determine whether the gene will confer sensitivity. Stable cell lines were established to overexpress SULT1A1 in H1299 and Saos-2 lines. Both lines natively have low SULT1A1 expression and are insensitive to N-BICs. As shown in Figure 3B , Saos-2 cells overexpressing SULT1A1 become sensitive to compound treatment. The same result was observed in H1299 cells (data not shown). This finding, along with the knockdown data, demonstrates that SULT1A1 is required for N-BICs efficacy as a tumor cell-killing compound.
SULT1A1 Activates N-BICs
We hypothesized that cells with more SULT1A1 are able to convert the N-BICs efficiently to an electrophile at neutral pH by sulfonylating the free hydoxyl. The sulfate group is a better leaving group than the hydroxyl and can rapidly form the alkylating agent, which is then trapped by proteins in the cell ( Figure 4A ).
When synthesizing the compounds we noticed a susceptibility to acidic conditions under which the compounds would rapidly degrade, forming dimers or other multimers in solution. There is a literature precedent for the reactivity of I3C under acidic conditions, and this appears to translate to the benzylic analogs (Nguyen et al., 2010) . We found that the compounds were stable in buffered aqueous environments. We next decided to probe the ability of the compound to form any adducts with biologically relevant nucleophiles. Combining compound with glutathione under varying pH demonstrated the trend that pH was inversely correlated with reactivity. That is, acidic conditions promoted reactivity while basic conditions significantly hindered reactivity ( Figure S1 ). Of note, at physiological pH the reactivity is less than 5% of that at pH 4.5.
We built a structure-activity relationship (SAR) to better understand the correlation between compound reactivity and compound efficacy as measured by the ability to kill HCT116 cells. As noted in Figure 4B , compounds unable to form the elimination product electrophile were inactive, while those that did have the functionality to become an electrophile maintained the ability to kill HCT116 cells.
We demonstrated that N-BICs are substrates for purified SULT1A1 in vitro. Purified protein was combined with 3 0 -phosphoadenosine-5 0 -phosphosulfate (PAPS) and compound in the presence of 4-nitrophenol to measure the relative substrate reactivity with SULT1A1 (Frame et al., 2000) . N-BICs were found to be substrates of SULT1A1 via a method described in the literature ( Figure 4C ).
SULT1A1 Triggers N-BICs to Covalently Modify Cellular Proteins
To rule out a common artifact of differential permeability and/ or active efflux pumping, we looked at the relative intracellular concentrations of compound in the HCT116-isogenic cells. As seen in Figure 5A , compound resides in all three isogenic lines under steady-state conditions. In fact, it appears that HCT116-p53 null cells (compound resistant) have most free compound, and we speculate that this is because compound is unreactive in this cell line due to low SULT1A1 levels. We evaluated the levels of SULT1A1 in the isogenic lines and found that protein levels correlated well with sensitivity (Figure 5A ), supporting the notion that SULT1A1 effectively reduces the free pool of parental compound by conversion to an active form.
Next, we wanted to see whether the mechanism of action of the compound was due to targeting of a single protein or a more general, non-specific labeling. While exploring compound SAR, we found that larger changes in the region of the benzyl group were well tolerated. A naphthyl analog with a biotin tag appended to it (N-BIC 3, Figure 1A ) demonstrated good potency against HCT116 cells, with the same selectivity observed for N-BIC 1 ( Figure S2 ). This gave us a tool compound to further probe the reactivity of the compound in living cells. To identify the protein(s) covalently labeled with N-BIC 3, treated cells were lysed and total protein was run on SDS-PAGE and probed for the biotin tag. The compound labeled a discrete set of proteins. This labeling could be competed with a non-labeled compound, N-BIC 1 ( Figure 5B ). We next looked at subcellular localization. Cells were treated with N-BIC 3, fixed, washed, and probed for the biotin tag. As seen in Figure 5C , compound covalently modifies protein(s) throughout the cells and appears diffuse as readout by biotin tag staining. Staining intensity correlated with N-BIC reactivity. In addition, N-BIC 3 can be competed by pretreatment with non-labeled compound (N-BIC 1), thus preventing covalent modification with the biotin-tagged molecule.
Based on a publication studying the effects on reactive oxygen species by N-BICs type compounds (Wei et al., 2010) , we decided to recapitulate the results in our cells for orthogonal confirmation. Our results are in line with what (Wei et al., 2010) observed: particularly intriguing is the fact that polyphenolic antioxidants such as nordihydroguaiaretic acid (NDGA) were able to render cells insensitive to compound treatment, while other structural classes of antioxidants had no effect on compound efficacy, e.g., N-acetylcysteine (NAC) ( Figure 5D ). In addition, N-BIC 1 reduced Nrf2 protein levels in HCT116-p53 mutant and WT cells but not in p53 null cells, which correlated well with their sensitivities to N-BICs ( Figure S3 ).
We then hypothesized that the polyphenolic antioxidants were able to act as competitive substrates with N-BICs for SULT1A1 (Figure 4) . The polyphenolic antioxidants are natural substrates for SULT1A1 (Wang and James, 2006) and can compete with N-BICs, thus preventing the ability of N-BICs to label proteins and kill cells. We found that treatment of cells with polyphenolic antioxidants precluded covalent modification of protein by N-BIC 3 ( Figure 5E ). Polyphenolic compounds such as quercetin are known potent substrates of purified SULT1A1 (Wang and James, 2006) .
N-BICs Do Not Accumulate In Vivo
As covalent modification can be a liability when designing a drug, we wanted to examine the in vivo metabolism of the compound.
To assess any accumulation concerns, we ran a mass balance experiment with radiolabeled compound. N-BIC 1 was labeled at the indole-2 position with 14 C. Tumor-bearing mice were given a single dose of compound and monitored for 6 days, after which they were euthanized and all samples collected. We found that 99% of the compound was recovered with 1% of the material remaining in the animal (Table S1) . Metabolic identification studies helped explain this efficient clearance of a compound with the potential for covalent modification in the animal. As seen in Figure 6A , the majority of the compound is oxidized at the methyl alcohol: first to the corresponding aldehyde, then to the acid. The acid can then be glucuronidated to aid in excretion. Of note, oxidation of the methyl alcohol blocks the compound's ability to become an electrophile, rendering that part of the molecule inert as shown in Figure 4 .
N-BICs Selectively Repress Tumor Growth
Interested in the selectivity of this compound class, we examined the in vivo efficacy of N-BIC 1 in tumor-bearing mice. In a preliminary pharmacokinetic and pharmacodynamic (PD) study in nude mice, we observed good exposure of the parent molecule in the tumor for up to 24 hr after a single dose. In addition, p21 induction was robust at earlier time points as a PD marker ( Figure 6B ). In the efficacy experiment, we found that N-BIC 1 could significantly slow the growth of HCT116-p53 mutant tumor xenografts (treatment/control ratio [T/C] = 0.59) ( Figure 6C) ; as well as HT-29 (T/C = 0.40) and Caov-3 (T/C = 0.35) xenograft models ( Figure S4 ). Furthermore, we tested that this effect was specific to cell lines sensitive to N-BIC 1 in vitro. As seen in Figure 6D , p53-null tumor xenografts were not affected by compound treatment and grew comparably with vehicle control tumors. A second arm of the study compared this directly with p53-mutant and N-BICs sensitive cells; their growth was significantly slowed by compound treatment (T/C = 0.5).
DISCUSSION
In an effort to identify compounds and targets that selectively target p53-mutant and/or null cell over WT, we identified the N-BICs, which selectively kill R248W engineered p53-mutant HCT116 cells preferably over p53-WT cells and have no effect on p53-null cells. N-BICs are synthetic analogs of the natural product I3C found in cruciferous vegetables, which has been shown in the literature to demonstrate antiproliferative effects on cancer cells with no known mechanism.
We identified a strong correlation between cell sensitivity to N-BICs and SULT1A1 expression levels in a broad set of cell lines from the CCLE collection, and confirmed that SULT1A1 is the required element to confer cellular sensitivity to N-BICs. SULT1A1 knockdown in p53-mutant cells results in loss of sensitivity to compound while overexpression of SULT1A1 renders insensitive p53-null cells sensitive to compound. The killing effect of N-BICs requires SULT1A1 expression, but to what extent this is correlated with p53 pathway status is unknown. It will be interesting to determine whether p53 affects SULT1A1 expression either directly or indirectly. We found that p53 null cells natively have low SULT1A1 protein levels. However, we found no correlation between p53 mutant or WT status with SULT1A1 expression levels (data not shown).
SULT1A1 is a member of the sulfotransferase family of phase II metabolic enzymes. Sulfotransferases increase compound solubility by transferring the sulfate group to their substrates, and N-BICs are one kind of substrate for SULT1A1. SULT1A1 converts the compound to an electrophile, which covalently modifies a range of proteins, ultimately leading to cell death. Variable SULT1A1 levels among cell types, tissues, and target local environments or structures (such as pH and accessibility) may confer specificity and selectivity to covalent modifiers including the N-BICs. Whether N-BICs can achieve a suitable therapeutic index to allow clinical application remains to be seen. Similar mechanisms are currently under investigation: aminoflavone (NSC 686288) is a compound known to be processed initially by cytochrome P450 and subsequently by SULT1A1 and SULT1A2 (Meng et al., 2006) . Its metabolites covalently modify cellular proteins and DNA, which leads to cell death. There is a good correlation between SULT1A1 expression and aminoflavone sensitivity. Clinical trials for aminoflavone are ongoing, although the outcome is unclear at present.
Small molecules have been reported in the literature to reactivate mutant p53 via a covalent modification mechanism. MIRA and PRIMA are two key examples functioning via mechanisms different from those of N-BICs. MIRA is an inherent electrophile containing a maleimide moiety, which decreases compound selectivity in protein binding and cell killing. PRIMA requires activation to an electrophile via a time-and temperature-dependent chemical mechanism. Again, this decreases the selectivity among which cells are killed by compound treatment. N-BICs have a more discrete triggering mechanism requiring enzymatic expression of SULT1A1. Cells with little or no SULT1A1 cannot convert N-BICs to the electrophile, and thus are not affected by compound treatment. In addition, we observed that PRIMA is not a substrate of SULT1A1 and MIRA is an inhibitor of the protein (data not shown), where N-BICs are substrates. It is possible that N-BICs, MIRA, and PRIMA induce cell death via similar mechanisms downstream of covalent modification; however, N-BICs afford cell line selectivity based on SULT1A1 expression levels. Furthermore, we found that N-BICs reduce Nrf2 in sensitive cells but not in insensitive cells, which indicates that depriving the cells of Nrf2 may contribute to the loss of cell viability.
There is reasonable concern for compound accumulation when introducing a compound with a covalent mechanism of action into animals. The combination of the N-BICs trigger mechanism and in vivo metabolism renders them relatively safe and efficiently cleared from the majority of the mouse body. Accumulation in animals due to covalent modification was not found via radiolabeled mass balance experiments. Oxidation of the N-BICs by phase I enzymes renders the compound unable to convert to the electrophile by SULT1A1 activation, and makes it more amenable to excretion by modification to the glucuronidate. At the same time, enough compound could reach the implanted tumor to elicit an effect. This allays any concerns and demonstrates the specificity triggered by the enzyme location. Furthermore, we demonstrated that tumor growth was significantly repressed by N-BICs treatment. In combination, the N-BICs show promise as a selective cancer therapeutic based on SULT1A1 levels.
We observed a trend that p53-mutant cells have relatively high SULT1A1 levels. One future direction would be to investigate the correlation between p53 status and SULT1A1 levels. This selectivity mechanism via SULT1A1 activation of compound could lead to therapeutics for tumors that are p53-mutant, which represents an unmet medical need. In conclusion, the N-BICs show promise as a selective cancer therapeutic based on SULT1A1.
SIGNIFICANCE
The mechanism for I3C's antiproliferation in cancer cells remains uncertain. Understanding this mechanism of action would be of great value to cancer treatment. Our computational analysis of cell line profiling of about 500 cell lines identified for the first time SULT1A1 as the essential factor. We unambiguously proved that N-BIC sensitivity is dependent on SULT1A1 protein. Furthermore, we showed how N-BICs kill cells. We found that SULT1A1 converts the inactive prodrugs, N-BICs, to strong electrophiles, to alkylate many proteins for the killing of sufficient tumor cells. We also found that there is little retention of N-BIC metabolites in vivo. Therefore, N-BICs promise to be potential therapeutic candidates for patients with tumors with high levels of SULT1A1 protein expression.
EXPERIMENTAL PROCEDURES Chemical Synthesis
Detailed synthetic information for N-BIC 1, 2, and 3 can be found in the Supplemental Information. Characterization of the novel compound N-BIC 13, 166.19, 138.50, 138.05, 137.20, 134.35, 134.19, 129.51, 129.39, 129.18, 128.71, 127.65, 127.16, 126.67, 123.05, 120.52, 120.37, 116.66, 111.11, 63.27, 61.63, 57.19, 57.04, 50.98, 44.32, 41.15, 36.86, 29.69, 29.46, 27.02 (s, 1 C Cell Culture Caov-3, HLE, HLF, and HUH1 were maintained in DMEM (Invitrogen, #11995). H1299 and SNU475 were maintained in RPMI-1640 medium (Invitrogen, #11875). C3A and Hep_G2 were cultured in EMEM (ATCC, #30-2003) . Saos-2, HT29, and HCT116 cells were cultured in McCoy's 5A medium (Invitrogen, #16600). All media were supplemented with 10% fetal bovine serum.
Cell Viability Assay
Cells were seeded to 384-well plates at 20,000 cells for liver cell lines, 8,000 cells for Caov-3, and 4,000 cells for all other cell lines in 36 ml of medium and treated with 4 ml of compounds on the second day. Cell viability was determined with CellTiter-Glo Luminescent Cell Viability Assay (Promega, #G7572) after 72 hr of treatment.
Colony Formation Assay
HCT116 p53 Mut cells (1,000 cells in 3 ml of medium) were seeded onto sixwell plates and treated with indicated compounds. Medium and compound were refreshed every other day. At day 13, cells were washed with PBS, fixed, and stained in Crystal Violet staining solution for 30 min. After washing with PBS, plates were dried and scanned.
SULT1A1 Knockdown with shRNA shRNA lentiviral plasmids (shRNA1, 5 0 -CCG GGA CAT GAA GGA GAA CCC GAA ACT CGA GTT TCG GGT TCT CCT TCA TGT CTT TTT G; shRNA2, 5 0 -CCG GAC GCA AAG GAT GTG GCA GTT TCT CGA GAA ACT GCC ACA TCC TTT GCG TTT TTT G; shRNA3, 5 0 -CCG GAG TTT CCT ACT ACC ACT TCT ACT CGA GTA GAA GTG GTA GTA GGA AAC TTT TTT G) and pLKO.1-puro Non-Target shRNA control plasmid DNA (SHC016) were purchased from Sigma. Lentiviral particles were made by co-transfection of viral packaging constructs VSVG and Delta 8.9 and shRNA lentiviral plasmids into 293T cells, and collected at 48 and 72 hr. Lentiviral particles (1 ml) were then added to the cells in 2 ml of Polybrene (8 mg/ml). 48 hr after infection, 1 mg/ml puromycin was applied for selection of stable cell lines.
Western Blotting
Cell pellet was lysed in 50 mM Tris-HCl (pH 7.4), with 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100, plus protease inhibitor cocktail (Roche, #11836153001). The cell lysate was separated on Criterion Tris-HCl precast Gels (Bio-Rad, #345-0033) and transferred to Nitrocellulose membranes. The membranes were blocked with 10% fat-free milk in Tris-HCl buffered saline plus 0.1% Tween 20 (TBST) for 1 hr. They were then incubated with either goat anti-SULT1A1 antibody (R&D, #AF5546) at 1:250 dilution, mouse anti-p53 (Santa Cruz Biotechnology, #sc-126) at 1:1,000 dilution, rabbit anti-Nrf2 antibody (EP1808Y) (Abcam, #ab62352) at 1:500 dilution, or mouse anti-b-actin (Sigma, #A1978) at 1:20,000 dilution in 10% milk in TBST at 4 C overnight. After three 10-min washes with TBST, the membranes incubated with donkey antigoat immunoglobulin-horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz, #sc-2020) at 1:500 dilution for SULT1A1 or with goat antimouse HRP-conjugated secondary antibody (Pierce, #31430) at 1:1,000 dilution for p53 and 1:40,000 dilution for b-actin, or with goat antirabbit HRP-conjugated secondary antibody (Pierce, #31460) at 1:1,000 dilution in 10% milk in TBST for 1 hr at room temperature. After three washes with TBST, the membranes were incubated with ECL Western Blotting Substrate (Pierce, #32106) and exposed to films.
Quantitative Real-Time PCR Total RNA was prepared using RNeasy mini (Qiagen, #74104). cDNAs were synthesized with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, #4368813). qPCR was performed with SYBR Green PCR Master Mix (Applied Biosystems, #4364346) and QuantiTect Primer Assay for SULT1A1 (Qiagen, #QT01665489) and b-actin (Qiagen, #QT01680476). SULT1A1 expression level was normalized to that of b-actin.
Biochemical SULT1A1 Assay
A colorimetric assay for SULT1A1 activity was adapted from Frame et al. (2000) . In brief, SULT1A1, PAPS, 2-Napthol, and test compound were combined in 2-(N-morpholino)ethanesulfonic acid buffer and incubated for various time periods. SULT1A1 uses PAPS to transfer a sulfate to the test substrate, with PAPS as a by-product. p-Nitrophenyl sulfate in the system can be used to regenerate PAPS from PAP. In doing so, p-nitrophenol is released, which is UV active and can be quantified. Reaction linear range was determined by taking absorbance readings at 405 nm (Envision plate reader, PerkinElmer) over a time course up to 3 hr.
Scheme modified from Frame et al. (2000) .
Detection of N-BIC-Binding Proteins
Cells were treated with N-BIC 3 or pretreated with test compounds for 3 hr and then treated with N-BIC 3 for 16 hr. N-BIC-binding proteins were detected with HRP-conjugated streptavidin (Pierce, #21130) by enhanced chemiluminescence or with Alexa Fluor 488 conjugated streptavidin (Invitrogen, #S11223) by fluorescence microscopy.
Measurement of N-BIC 1 Level in Cells
N-BIC 1 from cell lysate was analyzed by using high-performance liquid chromatography (HPLC) separation coupled with mass spectrometric detection. The detailed liquid chromatography-mass spectrometry (LC-MS) method is given in the Supplemental Information.
In Vivo Efficacy Experiments
All procedures involving laboratory animals were approved by the Novartis Institutes for Biomedical Research Institutional Animal Care and Use Committee, and were in accordance with federal, state, and local guidelines governing the use of laboratory animals in research. Female outbred athymic nu/nu mice, age 7 weeks (Taconic Farms) were inoculated subcutaneously, in the dorsal axillary region, with either 2 3 10 6 HT-29 or 2 3 10 6 HCT116 cells suspended in sterile media. Tumor volume was determined by caliper measurements obtained in two dimensions and calculated as width 2 3 length/2. Treatment was initiated when average tumor volume reached 100 mm 3 , after animal groups were randomized based on tumor volume.
Subsequent tumor volume and animal weight were measured every 3 or 4 days. N-BIC 1 was formulated in 10% ethanol, 10% Cremophore EL, and 20% Solutol in PBS, and delivered via intraperitoneal route for all experiments.
Pharmacokinetic Experiments
Detailed information on the LC-MS analysis of N-BIC 1 can be found in the Supplemental Information.
Measurement of N-BIC 1 in Mouse Tumor or Plasma
Tumor tissue was diluted 3-fold (w/w) with PBS/acetonitrile (85:15) and homogenized. A 25-ml aliquot of homogenized tumor or mouse plasma was subjected to protein precipitation. The supernatant was analyzed by HPLC separation coupled with mass spectrometric detection. Error bars represent the standard deviation from three replicates. Thirty micrograms of total cell lysate was resolved by SDS-PAGE gel, then transferred to a nitrocellulose membrane. Nrf2 and p53 protein levels were determined by rabbit anti-Nrf2 and mouse anti-p53 antibodies. C NMR spectra were recorded on Bruker AV-400 (400 MHz),
SUPPLEMENTAL INFORMATION
HPLC separation was performed using 1.0 mL/min flow rate with the gradient from 10% to 90% MeCN in 15 min, 0.1% NH 4 OH was used as the modifier in both the organic and aqueous phase. 3.0 x 100mm 3um C8 column.
General method for synthesis of N-benzyl indole-3-carbinols:
In a microwave vial was combined indole-3-carboxaldehyde (1.0 mmol), aryl methyl chloride/bromide (1.5 mmol), and cesium carbonate (2.5 mmol) in DMF (Volume: 1.5 mL). The vial was sealed and heated in the microwave to 160 ºC for 60 minutes. The reaction was partitioned between EtOAc and water. The organic layer was extracted, washed with brine, dried over Na 2 SO 4 and the solvent removed in vacuo. The crude product was dissolved MeOH (Volume: 4 mL). Sodium borohydride (1.5 mmol) was added and the reaction was stirred at room temperature for 2 hours. The reaction was quenched with saturated aqueous NaHCO 3 and extracted twice into EtOAc. The combined organic layer was washed with water, then brine, dried over Na 2 SO 4 and the solvent removed in vacuo. Purification by preparative reverse phase HPLC delivered the desired N-benzyl indole-3-carbinol.
( 1-(pyridin-2-ylmethyl)-1H-indol-3-yl) 50, 149.19, 137.02, 136.30, 127.19, 127.15, 122.56, 121.31, 121.19, 119.23, 118.71, 115.99, 109.96, 55.27, 50 52, 136.07, 130.19, 128.61, 127.15, 126.77, 121.15, 119.18, 118.54, 115.73, 113.84, 110.02, 55.26, 55.03, 48 
Synthesis of N-BIC 3:
Indole 3-carboxaldehyde (100 mg, 0.689 mmol) was dissolved in THF (Volume: 5 mL) and cooled to 0 ºC under a nitrogen atmosphere. Sodium hydride (60% dispersion in oil, 41.3 mg, 1.033 mmol) was added, causing gas to evolve and the reaction turned pink in colour. This was stirred cold for 5 minutes, then 6-(bromomethyl)-2-naphthonitrile 25 (170 mg, 0.689 mmol) was added. This was stirred at RT for 90 minutes, then quenched with water and extracted twice into EtOAc. The combined organic layer was washed with water, then brine, dried over Na 2 SO 4 and the solvent removed in vacuo. The crude material (200 mg) was divided into two separate batches and utilized as follows. The material (100 mg, 0.322 mmol) was suspended in THF (5 ml). LiAlH 4 (1M in THF, 0.483 ml, 0.483 mmol) was added dropwise (causing gas to evolve) and the reaction was slowly heated up to reflux for 2 hours. A beige precipitate crashed out upon heating, so vigorous stirring was maintained. The reaction was then cooled to RT and quenched with dropwise addition of 1N NaOH (~10 mL). This was stirred for 15 minutes, or until the solid dissolved, then the product was extracted three times into EtOAc. The combined organic layer was washed with water, then brine, dried over Na 2 SO 4 and the solvent removed in vacuo. This delivered 63 mg (62% yield) of intermediate amine A as a yellow powder which can be used without purification. 
